OceanEnergy

Ocean Biomedical is a biopharmaceutical company focused on the discovery and development of innovative therapeutic products in oncology, infectious diseases, and fibrosis. The company operates through a unique scientific partnership model, collaborating with leading research universities to advance high-potential discoveries into clinical-stage candidates. Its lead programs include a novel malaria vaccine targeting the PfGARP protein and a suite of immunotherapy candidates targeting CHI3L1 for the treatment of non-small cell lung cancer and glioblastoma. In 2025, the company announced a strategic expansion into power infrastructure and digital assets to generate diversified revenue streams to support its core biomedical research mission.